- Home
- IOVA vs NCMI Comparison
IOVA vs NCMI Comparison
Compare IOVA & NCMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NCMI
- Stock Information
- Founded
- IOVA 2007
- NCMI 2005
- Country
- IOVA United States
- NCMI United States
- Employees
- IOVA N/A
- NCMI N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NCMI Advertising
- Sector
- IOVA Health Care
- NCMI Consumer Discretionary
- Exchange
- IOVA Nasdaq
- NCMI Nasdaq
- Market Cap
- IOVA 1.0B
- NCMI N/A
- IPO Year
- IOVA N/A
- NCMI 2007
- Fundamental
- Price
- IOVA $3.61
- NCMI $5.89
- Analyst Decision
- IOVA Strong Buy
- NCMI Strong Buy
- Analyst Count
- IOVA 9
- NCMI 5
- Target Price
- IOVA $18.22
- NCMI $7.60
- AVG Volume (30 Days)
- IOVA 10.0M
- NCMI 883.6K
- Earning Date
- IOVA 05-08-2025
- NCMI 05-06-2025
- Dividend Yield
- IOVA N/A
- NCMI 0.51%
- EPS Growth
- IOVA N/A
- NCMI N/A
- EPS
- IOVA N/A
- NCMI N/A
- Revenue
- IOVA $164,070,000.00
- NCMI $240,800,000.00
- Revenue This Year
- IOVA $182.20
- NCMI $15.11
- Revenue Next Year
- IOVA $62.10
- NCMI $9.16
- P/E Ratio
- IOVA N/A
- NCMI N/A
- Revenue Growth
- IOVA 13698.99
- NCMI 45.76
- 52 Week Low
- IOVA $2.70
- NCMI $4.12
- 52 Week High
- IOVA $14.23
- NCMI $7.60
- Technical
- Relative Strength Index (RSI)
- IOVA 54.38
- NCMI 49.63
- Support Level
- IOVA $2.89
- NCMI $5.70
- Resistance Level
- IOVA $3.43
- NCMI $5.99
- Average True Range (ATR)
- IOVA 0.30
- NCMI 0.26
- MACD
- IOVA 0.10
- NCMI 0.02
- Stochastic Oscillator
- IOVA 95.60
- NCMI 67.19
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.